Smarter leaders trust GlobalData

Data Insights Innovation in pharma: GLP-1 analogues

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Moderna Inc

Alkermes Plc

Hanmi Science Co Ltd

Orgenesis Inc

BioAtla Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

GLP-1 analogues is a key innovation area in the pharmaceutical industry, particularly in the field of metabolic disorders

GLP-1 analogues refer to synthetic compounds that mimic the action of the naturally occurring hormone GLP-1. GLP-1 is released by the intestines in response to food intake to stimulate insulin secretion and helps regulate blood glucose levels. By mimicking GLP-1’s action, GLP-1 analogues can help treat metabolic disorders where insulin secretion is impaired such as Type 2 diabetes and obesity.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 335+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of GLP-1 analogues.

Key players in the GLP-1 analogues space – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to GLP-1 analogues space

Hanmi Science is one of the leading patent filers of GLP-1 analogues, and the company has several GLP-1 analogues in late-stage clinical development. Some of its top pipeline GLP-1 analogue drugs are efpeglenatide, efinopegdutide and efocipegtrutide. Apart from these drugs, the company is also developing other combination drugs and other GLP-1 analogues and has filed multiple patents for these assets.

In terms of application diversity, Orgenesis leads the pack, while BioAtla and ImCyse stood in the second and third positions, respectively.

By means of geographic reach, Rubius Therapeutics held the top position, followed by Vectus Biosystems and Moderna.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.